Associated tags: FDA, GRB2, Acute myeloid leukemia, Bone marrow, IND, RNA interference, STAT3, Lymphoma, Holding, Pharmaceutical industry, Patient, AML
Locations: GA, BELLAIRE, TX, US, UNITED STATES
ET to report financial results for the second quarter ended June 30, 2019 and to provide a business overview.
Key Points:
- ET to report financial results for the second quarter ended June 30, 2019 and to provide a business overview.
- A live audio webcast of the call will also be available on the Presentations section of the Companys website, www.biopathholdings.com .
- An archived webcast will be available on the Bio-Path website approximately two hours after the event.
- The Company is also developing BP1002, which targets the Bcl-2 protein and is expected to be evaluated for the treatment of lymphoma and solid tumors.
Health,
Biotechnology,
Oncology,
Pharmaceutical,
Finance,
Financial markets,
Money,
Stock market,
Corporate finance,
Initial public offering,
Equity securities,
U.S. Securities and Exchange Commission,
Shelf registration,
Prospectus,
Registration statement,
Stock In a registered direct offering, Bio-Path issued and sold 712,910 shares of its common stock for a price of $25.95 per share, for aggregate gross proceeds of approximately $18.5 million.
Key Points:
- In a registered direct offering, Bio-Path issued and sold 712,910 shares of its common stock for a price of $25.95 per share, for aggregate gross proceeds of approximately $18.5 million.
- Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
- The shares of common stock described above were offered and sold by Bio-Path pursuant to a shelf registration statement on Form S-3 (Registration No.
- The offering of the shares of common stock was made only by means of a prospectus supplement that forms a part of the registration statement.
